ARTICLE | Clinical News

ISPH's INS365 misses Phase III endpoint

January 16, 2002 8:00 AM UTC

Inspire (ISPH) said its INS365 ophthalmic eye drops to treat dry eye showed no difference between treatment and placebo groups on the primary efficacy endpoint in a 558-patient U.S. placebo-controlled Phase III trial. According to ISPH, the placebo effect in the Phase III study was higher than in the company's Phase II trial. ...